Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD) are the intermittent flares of COPD disease, characterized by increased cough, increased breathing difficulty and oxygen requirement. AECOPD frequently results in hospitalizations and contributes to declining lung function over time. AECOPD is driven largely by neutrophils, the most destructive white blood cell. Current treatment includes steroids, antibiotics and bronchodilators, none of which address the key mechanism of lung injury driven by neutrophils.
The dual-targeting mechanism of RLS-0071 (pegtarazimod), ReAlta’s lead compound, is well suited for treating this acute inflammatory disease, and potentially many related pulmonary disorders that all have a high unmet medical need.
Pegtarazimod has demonstrated powerful and rapid inhibition of neutrophils in a preclinical model, of acute lung injury a model associated with AECOPD. In this model, rats treated with pegtarazimod after the injury had an 85% reduction in lung injury as shown in the graphic below.
Important downstream anti-inflammatory benefits were also achieved in the AECOPD animal model decreasing multiple pro-inflammatory cytokines as depicted in the graphic below.
RLS-0071 (pegtarazimod) recently completed a human trial modeling AECOPD via inhalation of an inflammatory agent (LPS). This trial showed excellent translation of our animal model to human. In this AECOPD human model, pegtarazimod dramatically decreased neutrophil infiltration into the lungs, decreased multiple key drivers of lung tissue damage and markers of lung injury. Results from this study were presented at the American Thoracic Society in May 2023.
More information on the study results can be found here
Our Goals:
ReAlta is currently enrolling a Phase 2 trial for RLS-0071 (pegtarazimod) in hospitalized patients with AECOPD. More information about this trial is available on clinicaltrials.gov (NCT06175065). https://clinicaltrials.gov/study/NCT06175065
Hypoxic-ischemic encephalopathy (HIE) is a type of newborn brain damage caused by oxygen deprivation and limited blood flow.
Learn More
Acute Exacerbations of COPD (AE COPD) affect individuals suffering from COPD, leading to worsening lung function and hospitalization. This inflammatory disease is primarily driven by neutrophils recruited into the lungs.
Learn More
Graft-versus-Host Disease (GvHD) is a common disease following bone marrow transplantation where the transplanted white blood cells begin to attack the host body including skin, liver and intestines.
Learn MorePlatelet Refractoriness is common in cancer patients who receive frequent platelet transfusions and increases the risk of life-threatening hemorrhage.
Learn More